氨己烯酸片的副作用有哪些？怎么缓解？

Vigabatrin is an analogue of gamma-aminobutyric acid (GABA), which can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in the concentration of GABA in the brain, thus exerting anti-epileptic effects. Clinically, vigabatrin tablets Vigabatrin are used to treat epilepsy in which other anti-epileptic drugs are ineffective, especially partial seizures; Vigabatrin can also treat infantile spasms (West syndrome, West syndrome). 

Vigabatrin is an irreversible GABA transaminase inhibitor that can increase the level of GABA in the brain and cerebrospinal fluid. It was developed in the 1980s. In 1989, the vigabatrin tablet Vigabatrin was approved in the UK. On August 21, 2009, the U.S. FDA approved Vigabatrin Tablets (Vigabatrin) as a monotherapy for pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy.

What are the side effects of vigabatrin tablets? How to relieve it?

Vigabatrin tablets have significant therapeutic effects, but taking this drug for treatment will also produce certain side effects or adverse reactions. Common ones include: fatigue/drowsiness/headache/dizziness/mental confusion/depression, etc. Since each patient's physical condition is not exactly the same, the degree of side effects of using vigabatrin tablets is not entirely the same. If serious side effects occur, please contact your doctor in time.

The use of vigabatrin tablets and vigabatrin should be done under the guidance of an epilepsy expert or a child neurologist. Reactions after taking the medication should be reported to the doctor promptly. Treatment with Vigabatrin may affect your ability to drive and use machinery. Generally, patients with uncontrolled epilepsy are not allowed to drive or operate potentially dangerous machinery. In view of reports of drowsiness during clinical use of vigabatrin tablets Vigabatrin, patients should be warned before initiating treatment with this drug.

  Onset of vision loss is unpredictable and can occur within a few weeks of starting treatment, or earlier, or at any time during treatment (even months or years later), or after stopping Vigabatrin. Vision evaluation is recommended at baseline (no later than 4 weeks after starting treatment), at least every 3 months of treatment, and approximately 3-6 months after stopping treatment. If vision loss is documented, consider discontinuing the drug, balancing benefits and risks. Patients with other types of irreversible vision loss or those at high risk for them should not be treated unless the benefits of treatment clearly outweigh the risks.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: